2024-04-18 08:00:00 ET
Summary
- Sage Therapeutics' investigational drug for Parkinson's disease, dalzanemdor, failed in a Phase 2 trial, leading to a 20% drop in the stock.
- Despite FDA approvals for PPD treatments, Sage's revenue remains low, impacting financial stability and market expectations.
- Sage's financials show a strong balance sheet with significant cash reserves, though operational losses are substantial.
- Due to lower valuations and potential upcoming catalysts, I am upgrading SAGE stock from "Strong Sell" to "Hold".
Sage Therapeutics Faces Setbacks with Dalzanemdor Failure
Sage Therapeutics' ( SAGE ) stock is down 27% since my "Strong Sell" recommendation last November. At the time, I voiced concerns regarding the company's main offering, Zurzuvae, which treats postpartum depression (PPD); their risky pipeline that targets challenging indications like Parkinson's; and their high cash burn....
Read the full article on Seeking Alpha
For further details see:
Sage Therapeutics: Reassessing Investment Post Parkinson's Failure (Rating Upgrade)